• +1-646-491-9876
    • +91-20-67278686

    Search

    Ewing Sarcoma-Pipeline Review H1 2017

    Ewing Sarcoma-Pipeline Review H1 2017

    • Report Code ID: RW0001834367
    • Category Pharmaceuticals
    • No. of Pages 255
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Ewing Sarcoma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Pipeline Review, H1 2017, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape.

    Ewing's sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing's sarcoma can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site of the tumor after a seemingly minor injury.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Ewing Sarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 8, 21 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 2 and 2 molecules, respectively.

    Ewing Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Ewing Sarcoma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Ewing Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Ewing Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Ewing Sarcoma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Ewing Sarcoma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Ewing Sarcoma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Ewing Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 4
    Ewing Sarcoma - Overview 5
    Ewing Sarcoma - Therapeutics Development 6
    Ewing Sarcoma - Therapeutics Assessment 14
    Ewing Sarcoma - Companies Involved in Therapeutics Development 24
    Ewing Sarcoma - Drug Profiles 38
    Ewing Sarcoma - Dormant Projects 239
    Ewing Sarcoma - Discontinued Products 240
    Ewing Sarcoma - Product Development Milestones 241
    Appendix 249

    List of Tables

    Number of Products under Development for Ewing Sarcoma, H1 2017 11
    Number of Products under Development by Companies, H1 2017 13
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 14
    Number of Products under Development by Universities/Institutes, H1 2017 15
    Products under Development by Companies, H1 2017 16
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 17
    Products under Development by Universities/Institutes, H1 2017 18
    Number of Products by Stage and Target, H1 2017 20
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017 21
    Number of Products by Stage and Mechanism of Action, H1 2017 23
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017 24
    Number of Products by Stage and Route of Administration, H1 2017 26
    Number of Products by Stage and Molecule Type, H1 2017 28
    Ewing Sarcoma - Pipeline by Amgen Inc, H1 2017 29
    Ewing Sarcoma - Pipeline by Astellas Pharma Inc, H1 2017 29
    Ewing Sarcoma - Pipeline by Bristol-Myers Squibb Company, H1 2017 30
    Ewing Sarcoma - Pipeline by Cebiotex SL, H1 2017 30
    Ewing Sarcoma - Pipeline by Celgene Corp, H1 2017 31
    Ewing Sarcoma - Pipeline by Celldex Therapeutics Inc, H1 2017 32
    Ewing Sarcoma - Pipeline by CytRx Corp, H1 2017 32
    Ewing Sarcoma - Pipeline by EntreChem SL, H1 2017 33
    Ewing Sarcoma - Pipeline by Gradalis Inc, H1 2017 33
    Ewing Sarcoma - Pipeline by Incyte Corp, H1 2017 34
    Ewing Sarcoma - Pipeline by Leadiant Biosciences Inc, H1 2017 35
    Ewing Sarcoma - Pipeline by MacroGenics Inc, H1 2017 35
    Ewing Sarcoma - Pipeline by Merck & Co Inc, H1 2017 36
    Ewing Sarcoma - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017 36
    Ewing Sarcoma - Pipeline by NanoSmart Pharmaceuticals Inc, H1 2017 37
    Ewing Sarcoma - Pipeline by NantKwest Inc, H1 2017 37
    Ewing Sarcoma - Pipeline by Novartis AG, H1 2017 38
    Ewing Sarcoma - Pipeline by Oncomatryx Biopharma SL, H1 2017 38
    Ewing Sarcoma - Pipeline by Oncternal Therapeutics Inc, H1 2017 39
    Ewing Sarcoma - Pipeline by Pfizer Inc, H1 2017 39
    Ewing Sarcoma - Pipeline by Pharma Mar SA, H1 2017 40
    Ewing Sarcoma - Pipeline by Recombio SL, H1 2017 41
    Ewing Sarcoma - Pipeline by Shionogi & Co Ltd, H1 2017 41
    Ewing Sarcoma - Pipeline by Tarveda Therapeutics Inc, H1 2017 42
    Ewing Sarcoma - Pipeline by Tesaro Inc, H1 2017 42
    Ewing Sarcoma - Dormant Projects, H1 2017 244
    Ewing Sarcoma - Discontinued Products, H1 2017 245

    List of Figures

    Number of Products under Development for Ewing Sarcoma, H1 2017 11
    Number of Products under Development by Companies, H1 2017 12
    Number of Products under Development by Universities/Institutes, H1 2017 15
    Number of Products by Top 10 Targets, H1 2017 19
    Number of Products by Stage and Top 10 Targets, H1 2017 19
    Number of Products by Top 10 Mechanism of Actions, H1 2017 22
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 22
    Number of Products by Routes of Administration, H1 2017 25
    Number of Products by Stage and Routes of Administration, H1 2017 25
    Number of Products by Molecule Types, H1 2017 27
    Number of Products by Stage and Molecule Types, H1 2017 27
    Amgen Inc
    Astellas Pharma Inc
    Bristol-Myers Squibb Company
    Cebiotex SL
    Celgene Corp
    Celldex Therapeutics Inc
    CytRx Corp
    EntreChem SL
    Gradalis Inc
    Incyte Corp
    Leadiant Biosciences Inc
    MacroGenics Inc
    Merck & Co Inc
    Merrimack Pharmaceuticals Inc
    NanoSmart Pharmaceuticals Inc
    NantKwest Inc
    Novartis AG
    Oncomatryx Biopharma SL
    Oncternal Therapeutics Inc
    Pfizer Inc
    Pharma Mar SA
    Recombio SL
    Shionogi & Co Ltd
    Tarveda Therapeutics Inc
    Tesaro Inc

    Request for Sample

    Report Url http://www.reportsweb.com//ewing-sarcoma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//ewing-sarcoma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//ewing-sarcoma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments